Published in Ann Intern Med on May 18, 1999
Cost effectiveness analysis in health care: contraindications. BMJ (2002) 1.80
The economic burden of Clostridium difficile. Clin Microbiol Infect (2011) 1.74
Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost?: a computational simulation of Pennsylvania. BMC Public Health (2011) 1.56
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
The potential economic value of a human norovirus vaccine for the United States. Vaccine (2012) 1.23
Cost-effectiveness of implementing low-tidal volume ventilation in patients with acute lung injury. Chest (2009) 1.17
Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. Osteoporos Int (2005) 1.07
Economic model for emergency use authorization of intravenous peramivir. Am J Manag Care (2011) 0.89
Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. Br J Clin Pharmacol (2006) 0.88
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol (2005) 0.86
The potential economic value of a 'universal' (multi-year) influenza vaccine. Influenza Other Respir Viruses (2011) 0.82
Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J Gen Intern Med (2000) 0.82
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
High-priced technology can be good value for money. Ann Intern Med (1999) 0.79
Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J (2012) 0.78
Hospital versus home treatment of deep vein thrombosis in a tertiary care hospital in Saudi Arabia: Are we ready? Saudi Pharm J (2012) 0.77
Venous Thrombosis of the Upper Extremities. Curr Treat Options Cardiovasc Med (2001) 0.77
The new heparins. Ochsner J (2002) 0.76
Cost and utility of a low-molecular-weight heparin and unfractionated heparin for treatment of deep venous thrombosis in a Balkan country: A model analysis. Exp Clin Cardiol (2006) 0.75
Anticoagulation in patients with thromboembolic disease. Thorax (2001) 0.75
Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes: A Cost-Effectiveness Analysis. Medicine (Baltimore) (2015) 0.75
Diagnosis and treatment of deep vein thrombosis. West J Med (2000) 0.75
Automating and estimating glomerular filtration rate for dosing medications and staging chronic kidney disease. Int J Gen Med (2014) 0.75
DVT surveillance program in the ICU: analysis of cost-effectiveness. PLoS One (2014) 0.75
Cost-Effectiveness Analysis of Treatment Acute Deep Vein Thrombosis in Clinic of Vascular Surgery Sarajevo. Open Access Maced J Med Sci (2017) 0.75
Should we be measuring blood cholesterol levels in young adults? JAMA (1993) 3.57
Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA (1999) 2.33
Case mix, costs, and outcomes. Differences between faculty and community services in a university hospital. N Engl J Med (1984) 2.23
Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med (1997) 1.93
Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ (1997) 1.86
The new technology assessment. N Engl J Med (1990) 1.85
Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst (2000) 1.75
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med (1999) 1.72
Triglyceride concentration and coronary heart disease. BMJ (1994) 1.68
Screening for hypertension. Ann Intern Med (1990) 1.68
Developing and testing a multimedia presentation of a health-state description. Med Decis Making (1995) 1.68
Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax (2007) 1.68
Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med (1997) 1.66
Cost-effectiveness of automated external defibrillators on airlines. JAMA (2001) 1.52
Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. Ann Intern Med (1996) 1.50
The role of exercise testing in screening for coronary artery disease. Ann Intern Med (1989) 1.50
Using cost-effectiveness analysis to target cholesterol reduction. Ann Intern Med (2000) 1.45
Measurement of the validity of utility elicitations performed by computerized interview. Med Care (1997) 1.23
The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Qual Life Res (1997) 1.20
Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med (1997) 1.18
A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol (1992) 1.06
Making the most of Pap testing. JAMA (1998) 1.05
Alglucerase for Gaucher's disease: dose, costs and benefits. Pharmacoeconomics (1994) 0.98
The resting electrocardiogram as a screening test. A clinical analysis. Ann Intern Med (1989) 0.98
Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis (2001) 0.97
Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med (2000) 0.94
Clinical practice. Current approaches to cervical-cancer screening. N Engl J Med (2001) 0.94
Quality of life assessment software for computer-inexperienced older adults: multimedia utility elicitation for activities of daily living. Proc AMIA Symp (2002) 0.93
A randomized trial of computer-based reminders and audit and feedback to improve HIV screening in a primary care setting. Int J STD AIDS (2009) 0.93
Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther (2004) 0.93
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol (1996) 0.89
Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systems. Proc AMIA Annu Fall Symp (1997) 0.86
Problems with the report of the Expert Panel on blood cholesterol levels in children and adolescents. Arch Pediatr Adolesc Med (1995) 0.86
Multimedia quality of life assessment: advances with FLAIR. AMIA Annu Symp Proc (2005) 0.84
Computed tomography for nontraumatic headache: current utilization and cost-effectiveness. Can Assoc Radiol J (1993) 0.84
Triglyceride concentration and coronary heart disease. BMJ (1994) 0.83
Reappearance of specific colour patterns after nerve regeneration in Octopus. Proc R Soc Lond B Biol Sci (1974) 0.83
Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS (2009) 0.81
Mortality, hospital admissions, and medical costs of end-stage renal disease in the United States and Manitoba, Canada. Med Care (1997) 0.81
A concise review of the cost-effectiveness of coronary heart disease prevention. Med Clin North Am (2000) 0.81
Does cost-effectiveness analysis make a difference? Lessons from Pap smears. Symposium. Med Decis Making (2001) 0.80
Cost effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics (1998) 0.79
Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase. Int J Technol Assess Health Care (1992) 0.79
Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. Genet Test (1999) 0.78
No price too high? N Engl J Med (1992) 0.77
Visual preference and two-cue discrimination learning in octopus. Anim Behav (1972) 0.77
The inability of Octopus vulgaris to discriminate monocularly between oblique rectangles. Int J Neurosci (1971) 0.76
The cost of VA-sponsored research. Acad Med (1996) 0.76
Presentation and explanation of medical decision models using the World Wide Web. Proc AMIA Annu Fall Symp (1996) 0.76
Cholesterol screening in children and adolescents. Pediatrics (2000) 0.76
Triglyceride concentration and coronary heart disease. BMJ (1995) 0.75
Design of a modular, extensible decision support system for arrhythmia therapy. Proc AMIA Symp (1998) 0.75
Can technology assessment control health spending? Health Aff (Millwood) (1994) 0.75
Benefits versus profits: has the orphan drug act gone too far? Pharmacoeconomics (1994) 0.75
Chirality-selective excitation of coherent phonons in carbon nanotubes by femtosecond optical pulses. Phys Rev Lett (2009) 0.75
Long-term memory of a tactile discrimination in Octopus vulgaris and the effect of vertical lobe removal. Brain Res (1970) 0.75
Footsteps on a rocky path. J Christ Nurs (2000) 0.75
Is high-flux dialysis cost-effective? Int J Technol Assess Health Care (1993) 0.75
Long-term tactile memory in octopus: further experiments on the effect of vertical lobe removal. Brain Res (1970) 0.75
Disease Prevention Research at NIH: An Agenda for All. Workshop J: Prevention strategies, economic realities, and identification of prevention research needs. Prev Med (1994) 0.75